Drug Profile
Luliconazole
Alternative Names: 33525; 33525 cream; Lulicon; Lulicon Cream 1%; Lulicon Solution 1%; Lulifin; Luzu; NND-502Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Nihon Nohyaku
- Developer Ortho Dermatologics; POLA PHARMA; Sun Pharmaceutical Industries; Tinea Pharmaceuticals Inc
- Class Antifungals; Imidazoles; Skin disorder therapies; Small molecules
- Mechanism of Action Sterol demethylase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Mycoses; Tinea corporis; Tinea cruris; Tinea pedis
- Phase II/III Onychomycosis
Most Recent Events
- 27 Jul 2017 Valeant Pharmaceuticals International acquired Ortho Dermatologics in 2011 and changed the name of the later to Valeant Dermatology. Subsequently, in July 2017, it was rebranded to Ortho Dermatologics
- 08 Feb 2016 Launched for Tinea corporis (In children, In adolescents) in Honduras, Dominican Republic (Topical) before February 2016
- 16 Sep 2015 Antimicrobial data from a in vitro potency study in Onychomycosis released by TOPICA Pharmaceuticals